

BactiVac Network Management Oversight Board (NMOB)

Terms of Reference

Overall remit:

The BactiVac Network Oversight Management Board (NMOB) is responsible for devising and reviewing BactiVac Network strategy, making decisions related to its implementation, based on recommendations from the Operations Management Group and input from the Full Membership.

Terms of Reference:

1. To advise and support the Directors of the BactiVac Network in the strategic management and leadership of the network
2. To agree the plan for the establishment and delivery of the network, including the dissemination of information, encouraging widespread, open membership
3. To facilitate communication and ensure the effective co-ordination of all matters relevant to the running of the BactiVac Network and its activities, including interactions with other appropriate national and international organisations
4. To monitor the network's performance against all relevant targets and benchmarks, identifying action to encourage continuous improvement
5. To approve the distribution and awarding of network funding, including reviewing applications submitted for funding under the network's catalyst schemes
6. To have oversight over the commissioning of the two scoping exercises to address important knowledge gaps in bacterial vaccinology and utilise the findings, as appropriate, to guide the network's future strategy
7. To review BactiVac Network's risk register, including identification of action required to mitigate threats and to exploit opportunities

Duties of members of the Management Oversight Board:

- To act in the best interests of the BactiVac Network
- To take collective responsibility for implementation of the Management Oversight Board's decisions
- To act in good faith and with integrity
- To exercise due care and diligence
- To disclose and avoid any conflicts of interest
- To respect the confidentiality of those matters so classified
- Not to use their position to gain advantage for themselves or others
- Members are also expected to observe the 7 principles of public life identified by the Committee on Standards in Public Life (the Nolan Committee): selflessness, integrity, objectivity, accountability, openness, honesty, leadership.

Membership:

The constitution of the NMOB will be reviewed on an annual basis and revised, if required, based on the needs of the network in relation to any additional expertise required to successfully deliver the network's strategy. The expectation is that members of the NMOB will actively engage with the Network and attend a minimum of one meeting each year. The tenure of membership is for the duration of the current funding of the funding period i.e. until 31/03/27.

Name	Position	Institution/Company	Expertise
Calman MacLennan (Chair)	Professor of Vaccine Immunology	University of Birmingham	Human immunology, Bacterial vaccines
Adam Cunningham	Professor of Functional Immunology	University of Birmingham	Functional immunology, Mouse models
Constantino Lopez-Macias	Professor	National Medical Centre, Mexico City	Vaccine development in Latin America
Seanette Wilson	Science and Innovation Leader	Biovac Institute, Cape Town, South Africa	LMIC Vaccine Industry, DCVM
John McGiven	Senior Scientific Officer	APHA	Veterinary vaccines and diagnostics
Andrew Pollard	Director	Oxford Vaccine Group, University of Oxford	Vaccines, Challenge studies, Paediatrics
Alex Richter	Professor of Clinical Immunology	University of Birmingham	Vaccine responses in Secondary Immunodeficiency
Jo Dean	BactiVac Network Operations Manager	University of Birmingham	Operational and project management
Stephen Baker	Executive Director	IAVI	Enteric infections research
Birgitte Giersing* *Observer status	Technical Officer	World Health Organisation	Vaccine development and delivery
Francesca Micoli	Head of Technology Platform Unit	GSK Vaccines Institute for Global Health, Siena, Italy	Vaccine development and delivery
Ankur Mutreja	Senior Manager	Coalition for Epidemic Preparedness Innovations (CEPI)	Conjugate, vesicle and whole cell killed vaccines, antibodies, mucosal immunology
Elizabeth Klemm	Senior Scientific Manager	Novo Nordisk Foundation	Research development, host-pathogen interactions, global health and infectious disease
Mark Stevens	Professor of Microbial Pathogenesis	The Roslin Institute	Salmonella, E. coli and Campylobacter infections, pathogenesis and protection
Matt O'Shea	Consultant in Infectious Diseases and Clinical Microbiology & Senior Lecturer in Defence Pathology	University of Birmingham, UK	Infectious diseases and tropical medicine
Xin Tong	R&D Director	Walvax Biotechnology Co Ltd, China	Vaccine manufacture
Jeremy Salt	Chief Executive Officer	The Vaccine Group	Veterinary vaccines, technical development & Manufacturing, clinical trials, tropical medicine
V.Krishna Mohan	Executive Director	Bharat Biotech International, India	Vaccine manufacture
Adrian Shields	Clinical Lecturer	University of Birmingham	Clinical immunology and antibody response

***Observer status** - An individual who is permitted to attend and participate in meetings of the board of directors and to receive all information provided to members of the management oversight board (including minutes of board meetings), but who is not permitted to formally vote on matters submitted for a vote.

The Management Oversight Board may invite any person to attend its meetings, subject to the approval of the Chair of the Board.

Administrative support

- Susan Pope, BactiVac Network Administrator
- Evelina Balandyte-Shergill, BactiVac Network Administrator**
- Lauren Rawlins, BactiVac Network Administrator
- Guoda Garsvaite, BactiVac Network Communications Officer

Frequency of meetings:

The Management Oversight Board will meet quarterly, with the aim of holding 2 meetings face to face each year (one of which will be the Annual Network Meeting).

**** currently on maternity leave**